Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 2, 2012, Pages 208-213

  Imberti, Davide ^a   Gallerani, Massimo ^b   Manfredini, Roberto ^b  

^a Piacenza Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Apixaban; Knee replacement; Prophylaxis; Venous thromboembolism

Indexed keywords

APIXABAN; ENOXAPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; MALE; PYRAZOLES; PYRIDONES; VENOUS THROMBOEMBOLISM;

EID: 84865122094     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0716-8     Document Type: Article

References (13)

1. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:381S-453S (Pubitemid 351894916)
2. Randelli F, Biggi G, Della Rocca G et al (2011) Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. J Orthop Traumatol 12:69-76
3. NICE clinical guideline (2010). Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. www.nice.org.uk/guidance/CG92
4. Becattini C, Lignani A, Agnelli G (2010) New anticoagulants for the prevention of venous thromboembolism. Drug Des Dev Ther 4:49-60
5. Luettgen JM (2006) In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood 108(11):4130 (ASH Annual Meeting Abstracts)
6. Jiang X (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101(4):780-782
7. Raghavan N (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. DrugMetabDispos 37(1):74-81
8. Lassen MR (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5(12): 2368-2375 (Pubitemid 350154345)
9. Jiahao H, Cao Y, Liao C et al (2011) Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 105:245-253
10. Roser-Jones C, Becker R (2010) Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis 29:141-146
11. Galanis T, Thomson L, Palladino M, Merli G (2011) New oral anticoagulants. J Thromb Thrombolysis 31:310-320
12. Lassen MR (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594-604
13. Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375: 807-815